Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
25%
Ph phase_2
6
75%

Phase Distribution

0

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)
Other(1)

Detailed Status

Withdrawn3
Completed2
Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (75.0%)
Phase 32 (25.0%)

Trials by Status

completed225%
not_yet_recruiting225%
unknown113%
withdrawn338%

Recent Activity

0 active trials
Showing 5 of 8
withdrawnphase_2

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

NCT05582694
not_yet_recruitingphase_2

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

NCT04985890
withdrawnphase_3

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

NCT03149211
not_yet_recruitingphase_3

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

NCT04406727
unknownphase_2

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

NCT03164447
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05582694Phase 2

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Withdrawn
NCT04985890Phase 2

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

Not Yet Recruiting
NCT03149211Phase 3

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Withdrawn
NCT04406727Phase 3

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

Not Yet Recruiting
NCT03164447Phase 2

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

Unknown
NCT05056974Phase 2

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Completed
NCT04041362Phase 2

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

Withdrawn
NCT02369146Phase 2

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8